利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1041 条记录 (耗时 0.047 秒)

    SUPERAGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
    7.
    发明申请
    SUPERAGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 有权

    公开(公告)号：US20230002467A1

    公开(公告)日：2023-01-05

    申请号：US17825660

    申请日：2022-05-26

    申请人： The Board of Trustees of the Leland Stanford Junior University

    发明人： Christopher K. Garcia ,  Suman Mitra ,  Warren J. Leonard ,  Aaron M. Ring

    IPC分类号： C07K14/55 ,  A61K38/00

    摘要： Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor and a decreased binding capacity for IL-2Rγc receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

    CHIMERIC CYTOKINE MODIFIED ANTIBODIES AND METHODS OF USE THEREOF
    8.
    发明申请
    CHIMERIC CYTOKINE MODIFIED ANTIBODIES AND METHODS OF USE THEREOF 有权

    公开(公告)号：US20220380487A1

    公开(公告)日：2022-12-01

    申请号：US17770986

    申请日：2020-10-23

    申请人： Minotaur Therapeutics, Inc.

    发明人： Ruiqi Huang ,  Vaughn Smider

    IPC分类号： C07K19/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/715

    摘要： Provided are chimeric cytokine modified antibodies containing an ultralong CDR3, such as based on a bovine antibody sequence or a humanized sequence thereof, in which a portion of the CDR3 of the heavy chain is replaced by an interleukin (IL-15) or IL-2, and related antibodies. Among provided antibodies are chimeric IL-15 cytokine modified antibody molecules that are further linked or complexed with an extracellular portion of the IL15Rα, such as the IL15Rα sushi domain. Also provided are methods of making and using the chimeric cytokine modified antibodies.

    T-cell modulatory multimeric polypeptides and methods of use thereof
    10.
    发明授权
    T-cell modulatory multimeric polypeptides and methods of use thereof 有权

    公开(公告)号：US11505588B2

    公开(公告)日：2022-11-22

    申请号：US17749973

    申请日：2022-05-20

    申请人： Cue Biopharma, Inc.

    发明人： Ronald D. Seidel, III ,  Rodolfo J. Chaparro

    IPC分类号： C07K14/55 ,  A61K35/17 ,  C07K14/47 ,  C07K14/74 ,  A61K9/00 ,  C07K14/005 ,  G01N33/50 ,  A61K38/00 ,  A61K39/00

    摘要： The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.